Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 1
1993 1
1995 3
1996 2
1997 1
1998 1
1999 1
2000 3
2001 1
2002 2
2003 2
2004 1
2006 3
2007 2
2008 1
2009 1
2010 3
2011 7
2012 6
2013 7
2014 6
2015 2
2016 2
2017 10
2018 8
2019 14
2020 17
2021 25
2022 30
2023 34
2024 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary fibrosis: from pathogenesis to clinical decision-making.
Koudstaal T, Funke-Chambour M, Kreuter M, Molyneaux PL, Wijsenbeek MS. Koudstaal T, et al. Among authors: molyneaux pl. Trends Mol Med. 2023 Dec;29(12):1076-1087. doi: 10.1016/j.molmed.2023.08.010. Epub 2023 Sep 14. Trends Mol Med. 2023. PMID: 37716906 Review.
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.
George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U; Erice ILD working group. George PM, et al. Among authors: molyneaux pl. Lancet Respir Med. 2020 Sep;8(9):925-934. doi: 10.1016/S2213-2600(20)30355-6. Lancet Respir Med. 2020. PMID: 32890499
Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, Vo V, Renzoni EA, Wells AU, Garcia CK, Chua F, Newton CA, Molyneaux PL, Oldham JM. Pugashetti JV, et al. Among authors: molyneaux pl. Am J Respir Crit Care Med. 2023 Jan 1;207(1):69-76. doi: 10.1164/rccm.202201-0124OC. Am J Respir Crit Care Med. 2023. PMID: 35943866 Free PMC article.
Itaconate controls the severity of pulmonary fibrosis.
Ogger PP, Albers GJ, Hewitt RJ, O'Sullivan BJ, Powell JE, Calamita E, Ghai P, Walker SA, McErlean P, Saunders P, Kingston S, Molyneaux PL, Halket JM, Gray R, Chambers DC, Maher TM, Lloyd CM, Byrne AJ. Ogger PP, et al. Among authors: molyneaux pl. Sci Immunol. 2020 Oct 23;5(52):eabc1884. doi: 10.1126/sciimmunol.abc1884. Sci Immunol. 2020. PMID: 33097591 Free PMC article.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL; RECITAL Investigators. Maher TM, et al. Among authors: molyneaux pl. Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11. Lancet Respir Med. 2023. PMID: 36375479 Free article. Clinical Trial.
Lung function trajectory in progressive fibrosing interstitial lung disease.
Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, Tonkin J, Seede H, Echt G, Adegunsoye A, Chua F, Maher TM, Garcia CK, Strek ME, Newton CA, Molyneaux PL. Oldham JM, et al. Among authors: molyneaux pl. Eur Respir J. 2022 Jun 16;59(6):2101396. doi: 10.1183/13993003.01396-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34737223 Free PMC article.
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.
Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M, Braybrooke R, Molina-Molina M, Hobbs BD, Putman RK, Sakornsakolpat P, Booth HL, Fahy WA, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Whyte MKB, Zhang Y, Kaminski N, Adegunsoye A, Strek ME, Neighbors M, Sheng XR, Gudmundsson G, Gudnason V, Hatabu H, Lederer DJ, Manichaikul A, Newell JD Jr, O'Connor GT, Ortega VE, Xu H, Fingerlin TE, Bossé Y, Hao K, Joubert P, Nickle DC, Sin DD, Timens W, Furniss D, Morris AP, Zondervan KT, Hall IP, Sayers I, Tobin MD, Maher TM, Cho MH, Hunninghake GM, Schwartz DA, Yaspan BL, Molyneaux PL, Flores C, Noth I, Jenkins RG, Wain LV. Allen RJ, et al. Among authors: molyneaux pl. Am J Respir Crit Care Med. 2020 Mar 1;201(5):564-574. doi: 10.1164/rccm.201905-1017OC. Am J Respir Crit Care Med. 2020. PMID: 31710517 Free PMC article.
213 results